help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lal, S.
Right arrow Articles by Guyda, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lal, S.
Right arrow Articles by Guyda, H.

Journal of Clinical Endocrinology & Metabolism, Vol 41, 827-832, Copyright © 1975 by Endocrine Society

ARTICLES

Effect of clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone in the serum of normal men

S Lal, G Tolis, SB Martin, GM Brown and H Guyda

Clonidine (0.15 mg iv), a selective noradrenergic receptor agonist, increased serum growth hormone (GH) levels (greater than 6 ng/ml) on 8 out of 12 administrations to 6 normal men. This increase was independent of the hypotensive effects of the drug and unrelated to changes in serum cortisol. Clonidine induced a hyperglycemic effect in all subjects which was greatest 15 min after commencint the injection. No changes in blood sugar or GH occurred after placebo injection. Apomorphine, a selective dopamine receptor agonist, elevated GH in each of these 6 subjects (greater than 10 ng/ml). Clonidine had no effect on serum prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH), or thyroid-stimulating hormone (TSH). These data are compatible with a dual dopaminergic and noradrenergic mechanism modulating GH secretion in normal men and with the absence of a noradrenergic mechanism in the regulation of PRL, LH, FSH, or TSH.


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
G. R. McAnulty and G. M. Hall
Editorial II: Anaesthesia for the diabetic patient
Br. J. Anaesth., April 1, 2003; 90(4): 428 - 429.
[Full Text] [PDF]

Home page
 Br J AnaesthHome page
R. M. Venn, A. Bryant, G. M. Hall, and R. M. Grounds
Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit
Br. J. Anaesth., May 1, 2001; 86(5): 650 - 656.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Juul, K. W. Kastrup, S. A. Pedersen, and N. E. Skakkebak
Growth Hormone (GH) Provocative Retesting of 108 Young Adults with Childhood-Onset GH Deficiency and the Diagnostic Value of Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3
J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1195 - 1201.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
P. Glue, D. Nutt, and P. Glue
Clonidine challenge testing of alpha-2-adrenoceptor function in man: the effects of mental illness and psychotropic medication
J Psychopharmacol, January 1, 1988; 2(3-4): 119 - 137.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1975 by The Endocrine Society